Raman spectroscopy (RS) can identify cancerous breast tissue with 97.84% sensitivity and 97.18% specificity, according to a study published in Nature Scientific Reports. By analyzing the molecular signatures of tissue samples, the technology distinguishes between healthy tissue and three distinct cancer subtypes—invasive ductal carcinoma, invasive lobular carcinoma, and ductal carcinoma in situ—offering a potential path for more precise intraoperative margin assessment during breast-conserving surgery.
How Raman Spectroscopy Improves Surgical Precision
Surgeons performing breast-conserving surgery (BCS) currently rely on visual inspection and tactile feedback to identify tumor margins. This method carries a risk of leaving residual cancer cells behind. Research led by scientists using confocal Raman microscopy found that RS provides a non-destructive way to map tissue composition in real-time. By measuring the inelastic scattering of light, the device captures unique spectral signatures that differentiate healthy cells from malignant ones. Data from 80 tissue samples showed that the technology successfully classified subtypes with a specificity as high as 99%, providing a more objective tool for surgeons to determine if they have reached “clear margins.”
Raman spectroscopy works by hitting tissue with a laser and measuring how the light scatters. Because cancer cells have different chemical structures than healthy cells, they produce a distinct “fingerprint” in the light spectrum, allowing for near-instant identification.
Why Distinguishing Cancer Subtypes Matters for Patients
Not all breast cancers are identical, and identifying the specific subtype during a procedure influences long-term outcomes. The study highlighted the ability of RS to categorize invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and ductal carcinoma in situ (DCIS) with sensitivity ranging from 83% to 96%. According to the study authors, this capability is critical because pre-invasive disease like DCIS often presents differently than invasive forms. By identifying the exact histological subtype during surgery, medical teams can better tailor the amount of tissue removed, potentially reducing the need for repeat operations.
What Are the Next Steps for Clinical Adoption?
While the laboratory results for RS are promising, the next phase involves integrating confocal Raman microscopes into the operating room environment. Currently, the process requires ex vivo analysis, meaning the tissue is sampled and tested separately. Future trends in this field focus on developing fiber-optic probes that could allow for in vivo, real-time scanning while the patient is still under anesthesia. This transition would move the technology from a diagnostic tool to a navigational one, guiding the surgeon’s scalpel to ensure total tumor excision without unnecessary damage to surrounding healthy tissue.
Frequently Asked Questions
- What is the main benefit of Raman spectroscopy in surgery? It provides high-accuracy, real-time identification of cancerous tissue, helping surgeons achieve clear margins during breast-conserving surgery.
- How accurate is this technology? Based on the recent study, it achieved 97.84% sensitivity and 97.18% specificity in distinguishing cancerous from normal tissue.
- Is this technology currently used in hospitals? The technology is currently in the research and evaluation stage, focusing on ex vivo tissue classification before moving toward intraoperative use.
Patients interested in the latest advancements in breast cancer treatment should consult their surgical oncologist about clinical trials or new intraoperative margin assessment tools that may be available at major research hospitals.
Are you a healthcare professional or researcher interested in the intersection of photonics and oncology? Subscribe to our newsletter for the latest updates on surgical technology and cancer diagnostics.
Worth a look